Stroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher?
|
|
- Melvyn Alexander
- 7 years ago
- Views:
Transcription
1 Current Controversies 1165 Stroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher? Jonas Bjerring Olesen 1 ; Christian Torp-Pedersen 2 1 Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark; 2 Department of Health, Science and Technology, Aalborg University, Aalborg, Denmark Introduction For every patient with atrial fibrillation (AF) one of the first decisions to be made is whether to recommend anticoagulation. For this decision the physician needs to weigh the benefit of reducing the risk of thromboembolism against the risk of causing serious bleeding by treatment. Randomised controlled trials provide the strongest evidence and have in AF patients demonstrated that vitamin K antagonists (VKA) reduce the risk of (all) stroke/systemic embolism and all-cause mortality, when compared to placebo (1). These studies were conducted in patients with a placebo stroke rate of around 4.5 strokes per 100 years (1). In more recent studies comparing warfarin with the non-vka oral anticoagulants (NOACs), the warfarin event rate of stroke or systemic embolism varied between 1.5 and 2.4 per 100 years, and yet a significant reduction of stroke/ systemic embolism was still obtained with dabigatran and apixaban compared with warfarin (2). What perhaps really matters is whether a meaningful risk reduction can be obtained rather than the risk without treatment, and it is noteworthy that even the small risk of stroke or systemic embolism observed on warfarin in recent trials could be further reduced with the new agents. However, what the clinical trials do not tell us is where the threshold for starting Correspondence to: Prof. Christian Torp-Pedersen Department of Health, Science and Technology Aalborg University Niels Jernes Vej Aalborg, Denmark ctp@hst.aau.dk Received: February 19, 2015 Accepted after major revision: March 4, 2015 Epub ahead of print: March 6, Thromb Haemost 2015; 113: anticoagulation is. To aid this decision, stroke risk stratification scores have been developed to guide the clinician in decision-making. The CHADS 2 (Congestive heart failure, Hypertension, Age 75 years, Diabetes, previous Stroke) score is used in the American College of Chest Physicians (ACCP) (3) and Canadian guidelines (4) and the CHA 2 DS 2 -VASc (Congestive heart failure, Hypertension, Age 75 years, Diabetes, previous Stroke, Vascular disease, Age 65 years, Sex category [female]) used in European and National Institute of Clinical Excellence (NICE) guidelines (5). Both scores are easy to learn with one arguably being a bit more complex than the other with more risk factors. The use of two risk scores naturally generates a discussion as to which is better. Indeed, the randomised trials testing the NOACs against warfarin did not include many patients with a CHA 2 DS 2 -VASc score of 1, and hence these drugs have not been tested in all the patients currently recommended for anticoagulation by the European Society of Cardiology (ESC) and NICE guidelines. In this Viewpoint article, we will address this discussion by focusing on three principal questions: a) What is the stroke rate at various points of the risk scores in various populations; b) How should the scores be used and when to anticoagulate; and c) How best to move forward. What is the risk at different points of the CHADS 2 and CHA 2 DS 2 -VASc scores With one additional stroke risk factor (i.e. omitting female as the only risk factor with CHA 2 DS 2 -VASc, that is CHA 2 DS 2 -VASc score of 1 for males, 2 for females) is currently sufficient to generally recommend treatment with oral anticoagulation, especially with the NOACs and well managed VKA. With the latter, stroke and bleeding risks are low with good quality anticoagulation control, as reflected by a high time in therapeutic range (TTR), i.e. above 70% (6, 7). To strengthen a discussion we have shown the event rate of thromboembolism in relation to different points on the two scoring systems in Figure 1 and Figure 2. It is clear that there are differences even though all studies only investigated patients not treated with anticoagulation. Differences are likely driven by selection bias, a type of bias that the nationwide registries are less prone to. The CHADS 2 score Focusing on CHADS 2 it is clear that in the two Japanese cohorts (8, 9) as well as in the ATRIA cohort (10) the event rates with CHADS 2 scores of 0 and 1 are very low ( Figure 1). Notably, the overall stroke rate off-anticoagulation in these cohorts were even lower than on-warfarin in some of the trials (11), and much lower than the stroke rate observed in the placebo arms of the original warfarin studies (12, 13). Suzuki et al. found a stroke rate of 1.3 per 100 years, Okumura et al. a stroke rate of 1.5 per 100 years, and the ATRIA cohort found a stroke rate of 2.1 per 100 years. Nonetheless, when screening stable outpatients not selected for anticoagulation, for example, in the ATRIA cohort, the stroke rate will be markedly lower than in average patients with AF. Another possibility for the very low event rates found in the ATRIA cohort may be due to the methodological approach, e.g. conditioning on the future when including patients at the time of the first diagnosis with AF while presupposing that the patients will live until two diagnoses with AF (10). Also, ATRIA even excluded patients with no health plan membership after diagnosis of AF and those
2 1166 Olesen, Torp-Pedersen: Stroke risk in AF and CHADS 2 or CHA 2 DS 2 -VASc with no outpatient care during the 12 months after index date (14). Data from Framingham only demonstrated the stroke rate associated with a CHADS 2 score of 0 (15). Much higher stroke rates were observed in the US National Registry of Atrial Fibrillation (NRAF) study that relied on hospitalised cases (16). However, in this study Medicare beneficiaries who had acute AF and those <age 65 were excluded, which may explain the reduced risk compared to the Danish Figure 1: For available studies the graphs shows rate of stroke (or thrombosis) per 100 patient years for class of CHADS 2. and Swedish nationwide cohorts. Hospitalised AF patients also dominated the oneand 10-year risk of the Danish cohort (17) as well as the Swedish cohort (18). In the Danish cohort the stroke rates (including ischaemic stroke, transient ischaemic attack (TIA), and systemic thromboembolism) were 3.7 for men and 5.4 per 100 years for women (19), and in the Swedish cohort, the event rate was 4.5 per 100 years (18). Hence, in these unselected patient populations the event rates off-anticoagulation more closely resemble the true real world stroke rate for patients with AF. Examining these results combined makes it clear that in some studies a CHADS 2 score of 0 confers an event rate as high as that observed in the warfarin group of recent trials and in other studies a score of 1 hardly justifies anticoagulation. The CHA 2 DS 2 -VASc score Figure 2 shows similar data for CHA 2 DS 2 -VASc classification. The score was developed from the European Heart Survey (20) which included mainly outpatients. This study, as well as those by Suzuki (8) and Singer (10), display very low event rates at scores of 0 and 1. As expected from above, the Danish (17) and Swedish cohorts (18) demonstrate much higher risks, clearly indicating a possibility for benefit of anticoagulation with one additional stroke risk factor, that is, men with a CHA 2 DS 2 -VASc score of 1, or females with a CHA 2 DS 2 -VASc score of 2. However, the limitations with these registries are the lack of some clinical data and information on why the specific subject was not anticoagulated. Currently, the tipping point for when to recommend anticoagulation is set at 0.9 ischaemic strokes/systemic embolisms per 100 years (21). Even at a CHA 2 DS 2 -VASc score of 1, the net clinical benefit for anticoagulation is positive (22). Figure 2: For available studies the graphs shows rate of stroke (or thrombosis) per 100 patient years for class of CHA 2 DS 2 -VASc. Thromboembolic events A recent study by Friberg et al. elegantly displays the impact of changing the definition of the outcome event, i.e. using ischaemic stroke only or using a combination of ischaemic stroke, unspecified stroke, TIA, and pulmonary embolism (23). Unsurprisingly, narrowing the definition of the outcome reduced the headline event rate and with a CHA 2 DS 2 -VASc score of 1 the event rate ranged between 0.5 and 0.9 per 100 years, depending on the definition. The corresponding figures were not displayed for men and women separately which would have been valuable since women with a CHA 2 DS 2 -VASc score of 1 are not recommended anticoagulation. Unfortunately, it seems like the authors ex- Thrombosis and Haemostasis 113.6/2015 Schattauer 2015
3 Olesen, Torp-Pedersen: Stroke risk in AF and CHADS 2 or CHA 2 DS 2 -VASc 1167 Figure 3: Thromboembolic event rate with a CHADS 2 score of 0, 1, or 2 as dependent of which risk factor contributes to the score. cluded all patients at baseline if they initiated anticoagulation during follow-up, i.e. conditioning on the future, and this will lead to the exclusion of a number of subjects with an event. Indeed, AF patients are likely to initiate anticoagulation subsequent an ischaemic event. Also, a TIA should not be easily dismissed as such patients are at very high risk of a full-blown stroke, and in validated registries, administrative ICD-9 codes 434.XX, 433.X1, and V12.54 can have consistently high positive predictive values in identifying such patients with a confirmed cerebral event (24). Systemic embolism remains a highly relevant clinical endpoint in AF, reflecting which arterial tree the clot has ended up, and is significantly reduced by oral anticoagulation (25). How to use CHADS 2 and CHA 2 DS 2 -VASc It is clear from above that a score of 1 on either scale may represent patients that benefit or do not benefit from anticoagulation dependent on the population from where patients were selected. Different studies, from different time points or settings all contribute to the variation, but AF patients are far from static and the risk profile should be regarded as dynamic. AF patients have high rates of hospitalisation and additional stroke risk factors emerge along the way, which translate to a greater risk of adverse cardiovascular outcomes (26, 27). For many patients the decision for the clinician is easy regardless of which score is used, i.e. patients at increased risk profits from anticoagulation, and the effort should be placed on the minority where the benefit is marginal compared to the risk. Hence, the focus should be drawn the patients categorised as low risk of thromboembolism. Several studies (17, 18) have highlighted that the risk of thrombosis is highest immediately after diagnosis but Singer (28) suggests that the immediate risk category should not be part of decision. We disagree. The decision to anticoagulate takes into account also the near future and therefore the immediate risk is highly relevant. The question essentially raised is whether certain subpopulation should only receive temporary anticoagulation, a whole new question. Much discussion about stroke risk uses hazard ratios (HR), and we suggest this should be strongly discouraged in the evaluation of scores such as these where there is competing risk. The HR describes the immediate risk at any time and because of competing risk the same HR is much more important for a young than for an older individual where the risk of dying from unrelated causes is much greater. Nonetheless, an addition to just calculating a score the careful clinician will also take other data into account including the setting (29, 30). Consider an 80-year-old patient with known atherosclerosis admitted to hospital with AF, then this patient is naturally at higher risk compared to an otherwise healthy 80-year-old man where perhaps longstanding asymptomatic AF results in referral to the outpatient clinic,
4 1168 Olesen, Torp-Pedersen: Stroke risk in AF and CHADS 2 or CHA 2 DS 2 -VASc Figure 4: Thromboembolic event rate with a CHA 2 DS 2 -VASc score of 0, 1, or 2 as dependent on which risk factor contributes to the score. even though their stroke risk score may be identical. Even more important is the risk factors that make up a stroke risk score of 1 or 2. In Figure 3 and Figure 4 we have shown the event rate of thromboembolism is dependent on which component makes up a score of 0, 1, or 2 by CHADS 2 or CHA 2 DS 2 -VASc. Due to small numbers in several of the groups the estimates are associated with wide confidence limits, however, it would also be simplistic to suggest that all risk factors carry equal weight, and numerous studies have shown that this is not the case (29, 30). As not all risk factors are equal, by using a simple additive score, practicality and simplicity is gained at the cost of accuracy (17). For patients at low or intermediate risk of thromboembolism it is not wise to use any score rigidly, but the actual components providing the score, the clinical setting, the duration of AF and other factors, including patient values and preferences should be taken into account before making a decision (31). A recent study has shown that AF patients are desperate to avoid a stroke, and simply to avoid one stroke they are even prepared to sustain four major bleeds (32). How best to move forward Available studies of the relation between risk and actual use of anticoagulation (33) indicate a rather haphazard relation between use of anticoagulation and stroke risk, i.e. patients at higher risk of stroke do not have an increased usage of anticoagulation compared to patients at lower stroke risk (34). The main focus should therefore be on having physicians actually evaluate risk as part of the decision process rather than refining scores for the experts. Indeed, the European Society of Cardiology (ESC) guidelines de-emphasised the artificial categorisation into low, moderate and high risk strata, since stroke risk in AF is a continuum and a risk factor-based approach is recommended instead. More importantly, rather than a didactic use of scores to artificially categorise into treatment groups, the 2012 ESC guidelines and NICE guidelines recommended that the first step is to use identify the truly low risk patients (that is, CHA 2 DS 2 -VASc score 0 for males, 1 for females) who do not need any antithrombotic therapy. Subsequent to this step is to offer effective stroke prevention to AF patients with 1 additional stroke risk factors, and this means oral anticoagulation, whether this is well controlled VKA or treatment with a NOAC (5). For the future, we may perhaps need better risk scores. However, derivation of any new risk scores should rely on extremely large studies of patients with AF not treated with anticoagulation, which would be difficult to find these days. A new score(s) should use absolute risk over a clinically relevant length of time such as Thrombosis and Haemostasis 113.6/2015 Schattauer 2015
5 Olesen, Torp-Pedersen: Stroke risk in AF and CHADS 2 or CHA 2 DS 2 -VASc 1169 three or five years. All stroke risk factors do not necessarily carry equal risk, and it would be simplistic to assume otherwise. Conflicts of interest J. B. Olesen has received speaker fees from BMS and Boehringer Ingelheim, and funding for research from the Lundbeck Foundation, BMS, and The Capital Region of Denmark, Foundation for Health Research. C. Torp-Pedersen reports no conflicts of interest. This Viewpoint Article reflects the view of its author(s) and is not representative of the view of the Editorial Board or the Publishers. References 1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest 2012; 141: e531s-575s. 4. Verma A, Cairns JA, Mitchell LB, et al., Committee CCSAFG focused update of the canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol 2014; 30: Camm AJ, Lip GY, De Caterina R, et al focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace 2012; 14: Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: De Caterina R, Husted S, Wallentin L, et al. Vitamin k antagonists in heart disease: Current status and perspectives (section iii). Position paper of the esc working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013; 110: Suzuki S, Yamashita T, Okumura K, et al. Incidence of ischaemic stroke in japanese patients with atrial fibrillation not receiving anticoagulation therapy. Circ J 2014; Epub ahead of print. 9. Okumura K, Inoue H, Atarashi H, et al., Investigators JRR. Validation of cha(2)ds(2)-vasc and has-bled scores in japanese patients with nonvalvular atrial fibrillation: An analysis of the j-rhythm registry. Circ J 2014; 78: Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischaemic stroke and other thromboembolism in atrial fibrillation: The atria study stroke risk score. J Am Heart Assoc 2013; 2: e Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The copenhagen afasak study. Lancet 1989; 1: Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (cafa) study. J Am Coll Cardiol 1991; 18: Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (atria) study. Ann Intern Med 1999; 131: Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The framingham heart study. J Am Med Assoc 2003; 290: Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. J Am Med Assoc 2001; 285: Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. Br Med J 2011; 342: d Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in patients with atrial fibrillation: The swedish atrial fibrillation cohort study. Eur Heart J 2012; 33: Mikkelsen AP, Lindhardsen J, Lip GY, et al. Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study. J Thromb Haemost 2012; 10: Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: Eckman MH, Singer DE, Rosand J, et al. Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011; 4: Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the swedish atrial fibrillation cohort study. Circulation 2012; 125: Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a cha2ds2-vasc score of 1. J Am Coll Cardiol 2015; 65: Olson KL, Wood MD, Delate T, et al. Positive predictive values of icd-9 codes to identify patients with stroke or tia. Am J Manag Care 2014; 20: e Andersen LV, Lip GY, Lindholt JS, et al. Upper limb arterial thromboembolism: A systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs. J Thromb Haemost 2013; 11: Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: Report from the stockholm cohort study of atrial fibrillation. Europace 2011; 13: Friberg J, Buch P, Scharling H, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: Singer DE, Ezekowitz MD. Adding rigor to stroke risk prediction in atrial fibrillation. J Am Coll Cardiol 2015; 65: Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the cha2ds2-vasc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015; 65: Huang D, Anguo L, Yue WS, et al. Refinement of ischaemic stroke risk in patients with atrial fibrillation and cha2 ds2 -vasc score of 1. Pacing Clin Electrophysiol 2014; 37: Lane DA, Lip GY. Patient s values and preferences for stroke prevention in atrial fibrillation: Balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: e Le Heuzey JY, Ammentorp B, Darius H, et al. Differences among western european countries in anticoagulation management of atrial fibrillation. Data from the prefer in af registry. Thromb Haemost 2014; 111:
Introduction. Methods. Study population
New Technologies, Diagnostic Tools and Drugs Schattauer 2012 1 Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a real world atrial fibrillation
More informationStroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2
Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationPerioperative Bridging in Atrial Fibrillation: Is it necessary?
Perioperative Bridging in Atrial Fibrillation: Is it necessary? Jason B. Thompson M.D., Ph.D. August 29, 2015 2015 NCVH Birmingham Hypothesis: When bridging, risk of bleeding < risk systemic embolism (SE).
More informationThe Unmet Need of Stroke Prevention in Atrial Fibrillation in the Far East and South East Asia
Editorial The Unmet Need of Stroke Prevention in Atrial Fibrillation in the Far East and South East Asia Yutao Guo 1, Gregory Y. H. Lip 2, Stavros Apostolakis 2 Submitted: 20 Mac 2012 Accepted: 27 Mac
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationMEETING THE CHALLENGES IN ATRIAL FIBRILLATION MANAGEMENT: THE ROLE OF NEW ANTICOAGULANTS
MEETING THE CHALLENGES IN ATRIAL FIBRILLATION MANAGEMENT: THE ROLE OF NEW ANTICOAGULANTS Summary of Presentations from the Daiichi Sankyo Satellite Symposium, held at the Annual ESC Congress, Barcelona,
More informationEfficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation
New Technologies, Diagnostic Tools and Drugs 981 Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation An indirect comparison
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationFOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE
www.bpac.org.nz keyword: warfarinaspirin FOR THE PREVENTION OF ATRIAL FIBRILLATION RELATED STROKE Key Concepts In atrial fibrillation (AF) warfarin is more effective than aspirin for stroke prevention.
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationNHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationCHA 2 DS 2 -VASc Score and Heart Rate Predict Ischemic Stroke Outcomes in Patients with Atrial Fibrillation
Mini Forum for EPS Acta Cardiol Sin 2014;30:16 21 CHA 2 DS 2 -VASc Score and Heart Rate Predict Ischemic Stroke Outcomes in Patients with Atrial Fibrillation Chih-Shan Huang, 1 Chin-I Chen, 1 Ya-Ting Liu,
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationA focus on atrial fibrillation
A focus on atrial fibrillation Is being female really a risk factor for stroke? Dr Justin Mariani MBBS BMedSci PhD FRACP FCSANZ Consultant Cardiologist and Interventional Heart Failure Specialist Alfred
More informationNOAC S For Stroke Prevention in. Atrial Fibrillation. Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health
NOAC S For Stroke Prevention in Atrial Fibrillation Peter Cohn M.D FACC Associate Physician in Chief Cardiovascular Care Center Southcoast Health New Oral Anti Coagulant Formal Definition: Atrial Fibrillation
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationCosts and Benefits of Antithrombotic Therapy in Atrial Fibrillation in England: An Economic Analysis based on GRASP-AF
Costs and Benefits of Antithrombotic Therapy in Atrial Fibrillation in England: An Economic Analysis based on GRASP-AF Marion Kerr Insight Health Economics for NHS We would like to acknowledge PRIMIS who
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationAtrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital
Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial
More informationOral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Brief Comparison of Four Agents Abbreviations AF: Atrial fibrillation ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationAnticoagulation before and after cardioversion; which and for how long
Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationElisabetta Toso, MD Dipartment of Medical Sciences University of Turin
Security and efficacy of Rivaroxaban in real life in the prevention of the stroke in non valvular AF patients: presentation of the results of the international study Xantus Elisabetta Toso, MD Dipartment
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationNone. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015
Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet
More informationManaging the Patient with Atrial Fibrillation
Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS,
More informationLimitations of VKA Therapy
Fibrillazione Atriale Non Valvolare Ischemia o Emorragia le Due Utopie Rivali nella Scelta dei NAO Gianluca Botto, MD, FESC, UO Elettrofisiologia, Dip Medicina Limitations of VKA Therapy Unpredictable
More informationAtrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE
Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationDOI: 10.1016/j.thromres.2014.06.003 Document Version Author final version (often known as postprint)
Specific risk scores for specific purposes: Use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation Dzeshka, Mikhail S.; Lip, Gregory DOI: 10.1016/j.thromres.2014.06.003
More informationAtrial fibrillation: medicines to help reduce your risk of a stroke what are the options?
Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About
More informationOn route to 65......by optimising warfarin monitoring
On route to 65......by optimising warfarin monitoring Warfarin tried, trusted, underused Stroke significant costs to patients and the NHS In the UK, there are 12,500 strokes per year attributable to AF
More informationNICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues
NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues Andy Hutchinson Medicines Education Technical Adviser NICE Medicines and Prescribing Centre Note: this is
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationPrior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
More informationLe conferme dalla real life superano gli studi registrativi
Le conferme dalla real life superano gli studi registrativi E. Gronda, MD, FESC Cardiologyand and Research Unit IRCCS MultiMedicaSesto S. Giovanni CardiovascularDepartment MultiMedicaGroup. Rate (% / yr)
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationStroke Prevention in Patients with Atrial Fibrillation Dr. Karen Au Yeung June 2011 Volume 1 Issue 1 Doctors Academy Publications
Stroke Prevention in Patients with Atrial Fibrillation Dr. Karen Au Yeung June 2011 Volume 1 Issue 1 Publications Atrial fibrillation (AF) significantly increases a patient s risk of developing vascular
More informationBridging the Gap: How to Transition from the NOACs to Warfarin
Bridging the Gap: How to Transition from the NOACs to April 24 th 2015 UAN: 0048-0000-15-034-L01-P Amanda Styer, Pharm.D. Marion General Hospital, OhioHealth Objectives: 1. Review labeling regarding transition
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationBalanced information for better care. Atrial fibrillation. Anticoagulation: a key strategy Slow(er), even if not steady, wins the race
Balanced information for better care Atrial fibrillation Anticoagulation: a key strategy Slow(er), even if not steady, wins the race Atrial fibrillation increases the risk of stroke and other important
More informationSporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy?
Sporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy? Carina Blomström Lundqvist Dept Cardiology, Uppsala University, Sweden Patterns of AF Terminates
More informationRefining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
CHEST Original Research Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
More informationOAC and NOAC with or without platelet inhibition
Zürich 11.06.2015 Preoperative antithrombotic management OAC and NOAC with or without platelet inhibition Miodrag Filipovic miodrag.filipovic@kssg.ch Anästhesiologie & Intensivmedizin Case 1 76 yr old
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationGRASP-AF Coming to a PCT near you.
GRASP-AF Coming to a PCT near you. ADAS Anticoagulation dosing advisory service Blackpool Teaching Hospitals Trust Sean O'Brien; Anticoagulation Specialist BMS Grasp-AF and the implications on our Anticoagulation
More informationAF, Stroke Risk and New Anticoagulants
Carmarthen Cardiac Update Course AF, Stroke Risk and New Anticoagulants Dr Hamsaraj Shetty, B.Sc, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer University Hospital of Wales,Cardiff
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationAnticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice
Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice J. Jaime Caro,* MD CM; Kenneth M. Flegel, MD, MSc; Maria-Elena Orejuela,* BS; Heather E. Kelley,* MA; Jeanne
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationLong-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Advance Publication by-j-stage Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation
More informationAll Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation
All Wales Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation October 2013 This report has been prepared by a multiprofessional collaborative group, with support
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationSTROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE
STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE CASE REPORT: ACUTE STROKE MANAGEMENT 90 YEAR OLD WOMAN, PREVIOUSLY ACTIVE AND INDEPENDENT, CHRONIC ATRIAL FIBRILLATION,
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationNOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST
NOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST NGAIRE IS 70 YEARS OLD AND IN AF. SHE HAS NO MURMURS, NORMAL BLOOD PRESSURE, EGFR OF 65ML/MIN AND NO SIGNIFICANT PAST MEDICAL HISTORY. REGARDING
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationStroke prevention in AF: Insights from Clinical Trials and Real Life Experience
Stroke prevention in AF: Insights from Clinical Trials and Real Life Experience A. John Camm St. George s University of London and Imperial College London, UK Approval Number G.MA.GM.XA.10.2015.0723 Disclosure
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationRivaroxaban. Practical Experience in the Cardiology Setting. Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013
Rivaroxaban Practical Experience in the Cardiology Setting Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013 Overview of phase III clinical trials of new oral anticoagulants
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationThe warfarin dilemma Oral anticoagulation with warfarin in older people with atrial fibrillation
The warfarin dilemma Oral anticoagulation with warfarin in older people with atrial fibrillation 22 BPJ Issue 31 www.bpac.org.nz keyword: warfarin Atrial fibrillation and increasing age are both risk factors
More informationIndirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.019
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationCardiac Sources of Stroke. Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology
Cardiac Sources of Stroke Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology Stroke Pathophysiology Cardiologists Well Suited to Help 795K CVA per year, 87%
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationA Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation
Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation PATIENT EDUCATION GUIDE What is atrial fibrillation? Atrial fibrillation
More informationDepartments of Clinical Epidemiology and Biostatistics and of Medicine
Application for inclusion of novel oral anticoagulants for the treatment of non valvular atrial fibrillation in the WHO Model List of Essential Medicines 2015 Submitted by Ignacio Neumann, MD, PhD Holger
More informationService Specification Template Department of Health, updated June 2015
Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationHow To Understand How The Brain Can Be Affected By Cardiac Problems
Workshop 2e: Atrial Fibrillation, Heads and Hearts how the brain can be affected by cardiac problems Matthew Walters Heads and Hearts Cardiac disease and stroke Matthew Walters University of Glasgow Why
More information2. Background This indication of rivaroxaban had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the
More information